Xagenic Xagenic Raises $11.8M to Commercialize POC Dx Platform The company expects the funds to accelerate its efforts to develop and commercialize the Xagenic X1 diagnostic platform. U of Toronto Study Demos Electrochemical Clamp Chip for Detection of Circulating Nucleic Acids Premium The group has licensed the clamp method, as well as earlier technology developments, to Xagenic, which is working to commercialize it in various diagnostic areas. Xagenic Nabs Exclusive Rights to U of Toronto Mutation Detection Tech Electrochemical clamp assays, developed at the university could expand Xagenic's X1 platform into the liquid biopsy space. Xagenic Closes Series B Round Raising $23.8M NEW YORK (GenomeWeb) – Decentralized molecular diagnostics firm Xagenic today announced the second closing of its Series B financing round, bringing in a total of C$25.5 million (US$23.8 million). People in the News: Linda McAllister, Mostafa Ronaghi Premium Linda McAllister has joined Toronto-based molecular diagnostics firm Xagenic as chief medical officer. Dec 2, 2013 Xagenic Raises C$20M in Private Financing Round Jul 23, 2013 Seegene Seeks Partners to Develop Real-Time Array Technology for Point-of-Care Testing Market Premium Jun 25, 2013 U of Toronto Team Develops Next-Gen POC Pathogen Identification Chip Premium Feb 19, 2013 Canadian Government Provides MDx Firm Xagenic with $977K Jan 31, 2012 Xagenic Raises $10M to Develop Biochip System for Infectious Disease Testing Premium Jan 30, 2012 MDx Startup Xagenic Closes on $10M Series A Financing Round Jul 26, 2011 Startup Xagenic Receives $1.1M to Commercialize Chip-based MDx Technology Oct 19, 2010 Canadian Startup Xagenic Raises $1M to Fund Chip-Based Molecular Diagnostics Platform Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.